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The present investigation was aimed to design polyamidoamine (PAMAM) 
dendrimer having polyethylene glycol grafts as novel drug carrier.  In this study we 
successfully synthesized and conjugated PEGylated PAMAM dendrimers with anti HIV 
drug stavudine. Hemolytic toxicity studies were carried out for PEGylated PAMAM 
dendrimers which showed that haemolysis of cell was very negligible in PEGylated 
PAMAM dendrimers. Moreover surface were characterization of PEGylated PAMAM 
dendrimers was carried out TEM micrographs. Further physiochemical and physiological 
parameter such as UV, DSC, drug entrapment and drug release were carried out for 
PEGylated and non PEGylated PAMAM dendrimers. Drug loading, drug release and 
toxicity are better for PEGylated PAMAM dendrimers. 
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Poly (amidoamine) (PAMAM) 
dendrimers are a new class of 
nanomaterials with three-dimensional 
structure. The highly branched polymers 
consisted of three basic units including an 
ethylenediamine core, repeating units, and 
terminal units (Zeng and Zimmerman 1997; 
Newkome et al. 2001; Crooks et al. 2001). 
PAMAM dendrimers are synthesized 
through a serial repetition of two reactions: 
Michael addition reaction of amino groups 
to the double bond of methyl acrylate, 
followed by amidation of the resulting 
methyl ester with ethylene diamine (Zeng 
and Zimmerman 1997). Polyamidoamine 
(PAMAM) dendrimers are nanoscale 
biomaterials with highly controlled 
branched structures and monodispersed 
array (Mw/Mn < 1.01); they are recognized 
as a unique class of synthetic 
macromolecules replacing traditional 
synthetic polymers such as linear, cross-
linked, and branched polymers with 
relatively broad molecular weight 
distributions (Malik et al. 2000; Tomalia et 
al. 2002). 
The globular structure of PAMAM 
dendrimers can be divided into two parts: 
the surface that has primary amine groups 
and the interior that contains tertiary amine 
groups, which are closely related with the 
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capability of the complex formation with 
drug molecules and delivery effectively. 
The advantage of biodegradable and 
biocompatible polymers has increased the 
versatility of polymers in the design of 
polymeric drug delivery devices for many 
classes of bioactive agents. These polymers 
have been used in various macromolecular 
architectures: linear, cross-linked, and 
branched (Tomalia et al. 2003). A lot of 
interest has been shown, in recent time, in 
the use of dendrimers for the design of 
delivery systems for many classes of 
bioactive agents. Dendrimers offer a 
number of advantages compared to other 
architectural forms of polymers that have 
been used in drug delivery systems. They 
have narrow polydispersity; they are in the 
nanometer size range, which can allow 
easier passage across biological barriers 
(e.g., small enough to undergo 
extravasation through vascular endothelial 
tissues); host-guest chemistry can take place 
either in the interior (binding groups in the 
interior of dendrimers are called 
endoreceptors) or on the periphery of the 
dendrimer (groups involved in 
complexation chemistry on the periphery of 
the dendrimers are called exoreceptors) 
(Tomalia et al. 1990). 
However, PAMAM dendrimers are 
constrain to limit their applications because 
of their cytotoxicity, haemolysis and liver 
toxicity, which are thought that they are to 
interact with negatively charged cell surface 
(Neerman et al. 2004; Chen et al. 2004; Qiu et 
al. 2006; Zinselmeyer et al. 2002). 
Polyethylene glycols (PEG) were 
conjugated with various dendrimers to 
reduced cytotoxicity and incorporate the 
biocompatibility, and improve the 
physicochemical characteristics of them 
(Lee et al. 2005; Liu et al. 1999). Moreover it 
was verified that the chain length and the 
molar ratio of PEGs to PAMAM dendrimers 
could influence their drug-loading capacity 
(Hedden et al. 2003; Jevprasesphant et al. 
2003; Yang et al. 2004).     
Acquired immunodeficiency 
syndrome (AIDS) is a disease of the human 
immune system caused by the human 
immunodeficiency virus (HIV) (Broder et al. 
1984; Bowen et al.1985). This condition 
progressively reduces the effectiveness of 
the immune system and leaves the 
individual susceptible to opportunistic 
infection and tumor. It is transmitted 
through direct contact of a mucous 
membrane or the bloodstream with a bodily 
fluid containing HIV, such as blood, semen, 
vaginal fluid, pre-seminal fluid, and breast 
milk (Embretson et al. 1993; Price et al. 
1988). The antiviral therapy has unpleasant 
side effects, including peripheral 
neuropathy, acute pancreatitis, abdominal 
pain, diarrhoea, malaise, nausea, and 
fatigue. AIDS patients are generally treated 
with nucleoside or nucleotide reverse 
transcriptase inhibitors that inhibit reverse 
transcription by blocking the reverse 
transcriptase enzyme responsible for 
conversion from single-stranded RNA to 
double-stranded DNA in HIV.  Zidovudine, 
didanosine, zalcitabine, stavudine, 
lamivudine, and abacavir are nucleoside 
analogs and tenofovir and adefovir are 
nucleotide analogs used as reverse 
transcriptase inhibitors for HIV infection 
(Tavel et al. 1999).  
In the present study we selected 
short half-life and poor bioavailability drug 
stavudine (STV) and PEGylated PAMAM 
dendrimers as a drug carrier. Here drug 
stavudine was conjugated with PEGylated 
PAMAM dendrimers (G4 & G5) for 
delivery of a drug to overcome the 
problems of short half-life, poor 
bioavailability, and strong side effects.  
 
MATERIALS AND METHODS 
Materials 
MPEG2000 (Sigma, Germany), 
Ethylene diamine (EDA) and 
methylmethacrylate (CDH, India), 
methanol (Rankem, India), 4 dimethyl 
amino pyridine (sd-fine chemicals, India), 
Cellulose dialysis bag (MWCO 12-14 Kda, 
Himedia, India), stavudine was a 
benevolent gift from Hetro labs Ltd, India. 
PAMAM dendrimers G4 &G5 were 
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synthesised by divergent approach and 
extensively characterized as reported earlier 
in Prajapati et al.2009. All other chemicals 
were reagent grade and used without 
further modification.   
 
Synthesis and conjugation of MPEG 4-
Nitrophenyl Carbonate 
For the synthesis of M-PEG 4- nitro 
phenyl carbonate, polyethylene glycol was 
reacted with nitro phenyl carbonate 
(Kojima et al. 2000). Briefly the reaction was 
carried out by addation of THF (400ml) to 
M-PEG (0.05mmol) in gradual manner for 
1h and continues string for 48 h in room 
temperature. The resultant reaction mixture 
was evaporated to yield M-PEG 4 nitro 
phenyl carbonate. Recrystallization was 
carried out in chloroform – diethyl ether 
(10:1, total volume 300- 400ml) to yield 
purified form M-PEG 4 nitro phenyl 
carbonate.  
Further conjugation of G4 or G5 
PAMAM dendrimers with synthesised M-
PEG 4 nitro phenyl carbonate to produce 
PEGylated PAMAM dendrimers (Kojima et 
al. 2000). Briefly in dimethyl sulfoxide (1ml) 
PAMAM dendrimers G4 or G5 (0.5µmol) 
was dissolved and solution was stirred to 
react at room temperature for 3 to 6 days 
(based on the generation of PAMAM 
dendrimers and PEG modification ratio). 
Then resulted reaction mixture was 
dialyzed against distilled water for 72h. 
Lyophilisation of above solution will yield 
PEG-PAMAM dendrimer. 
 
Drug Loading and entrapment efficiency: 
Drug loading was carried out by 
dialysis method. Here PEGylated (G4 & G5) 
non PEGylated PAMAM dendrimer 
methanolic solution was taken in dialysis 
bag (mwco1000da sigma, Germany) and 
immersed in the aqueous solution of 
stavudine and incubated for 24 h at 25oC. 
The entrapment efficiency of dendrimer 
formulation were measured indirectly by 
spectrophotometrically estimating the 
amount of free drug in solution (λmax 
266nm) (uv.1601 shimadz  japan). Finally 
lyophilisation of content present in dialysis 
bag was done to produce drug loaded 
PEGylated and nonPEGylated dendrimer 
formulation (Vijayaraj Kumar et al. 2007).  
 
Morphology of the Dendrimers 
The surface morphology of 
PEGylated PAMAM dendrimers were 
charazatized by Transmission electron 
microscopy (TEM) studies. TEM studies can 
provide information about particle size and 
surface nature of stavudine loaded 
dendrimer nanoparticles. The TEM studies 
were carried out using 3mm Forman (10.5% 
plastic powder in amyl acetate) coated 
copper grid (300 mesh) at 60 Kv using 
negative staining by 2% phosphotungstic 
acid (PTA) for whole generation of 
dendrimers at 150,000X magnification on 
Philips CM-10 TEM and Fei-Philips 
Morayagni 268D with digital TEM image 
analysis system at 50-60 Kv. 
 
Differential Scanning Calorimetry 
Differential scanning calorimetry 
studies were carried out to view changes in 
thermal stability and crystallinty over range 
of temperature of stavudine loaded 
PEGylated PAMAM dendrimer, drug and 
PEGylated PAMAM dendrimer.  Briefly 
known quantity of sample was placed in an 
aluminium pan and crimped with lid. 
Further pan was placed in the sample cell 
for DSC module. (DSC Q10 V9.0 Build 275, 
TA Instruments, USA). Temperature in the 
DSC module was increased by 10°C/min 
from 35°C equilibrated temperature under a 
N2 gas purge. Temperature stability and 
phase transition of sample were obtained 
from peak in the resulting curve. 
 
 InvitroDrug Release studies 
The in vitro drug release of STV 
loaded PEGylated G4 and G5 PAMAM 
dendrimers were carried out by dialysis 
method. A known amount of STV loaded 
PEGylated G4 and G5 PAMAM dendrimers 
were packed in dialysis bags (MWCO 1000 
Da) were placed in 50 ml of PBS (pH 7.4) at 
37ºC with slow magnetic stirring under sink 
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conditions. Aliquots of 1 ml were 
withdrawn from the external solution and 
replaced with the same volume of fresh 
PBS. Finally drug concentrations in 
formulation determine spectro-
photometrically at 266nm λmax. 
 
Hemolytic Toxicity studies 
Hemolytic toxicity studies were 
carried out by earlier procedure reported in 
Vijayaraj Kumar et al. 2007.  RBC 
suspension from human blood with anti-
coagulant agent and normal saline were 
taken separately and incubated for 1hr to 
undergo hemolytic reaction. Here RBC 
suspension with hemolytic agents was 
considering as fully haemolysis of cell 
solution, as with normal saline no 
haemolysis cells solution. Hence these 
solutions were considered as standard 
solution. Briefly 0.5ml of STV loaded 
PEGylated and nonPEGylated dendrimer 
were added with 4.5ml of normal saline 
and incubated for 1hr 1h with RBC 
suspension. Further dendrimers solution 
was centrifugation and supernatants were 
taken and diluted with an equal volume of 
normal saline and absorbance was 
measured at 266nm. To obtain 0 and 100% 
hemolysis, RBC suspension was added to 5 
ml of 0.9% NaCl solution (normal saline) 
and 5 ml distilled water, respectively. The 
degree of hemolysis was determined by the 
following equation: 
 
Hemolysis (%) = Abs-Abso / Abs100-Abso × 100 
 
Where Abs, Abs100, and Abso are the 
absorbance of sample, a solution of 100% 
hemolysis, and a solution of 0% hemolysis; 
respectively. 
 
Stability Studies  
Stability studies were carried out for 
STV loaded PEGylated G4 and G5 PAMAM 
dendrimers. Here sample was stored in 40oc 
for three months. Drug content and drug 
release studies were carried out to analyze 
the stability of the formulation.  
 
 
RESULTS AND DISCUSSION 
Conjugation of MPEG-PAMAM 
Dendrimers 
The Conjugated synthesis of MPEG-
PAMAM dendrimers was confirmed by out 
by FT-IR, 1H-NMR and microscopic studies. 
In IR spectra, the MPEG-PAMAM 
dendrimers showed peaks at 3439 cm-1 for 
N-H stretching and 1379 cm-1 for N-H 
bending confirmed the Conjugation 
synthesis of MPEG-PAMAM dendrimers. 
The recorded IR spectra of representative 
MPEG 4-Nitrophenyl Carbonate showed 
nitro group band at 1432 cm-1 and aromatic 
band at 3012 cm-1. This peaks are missing in 
MPEG-PAMAM dendrimers, it’s clearly 
envisages that the nitro group and aromatic 
ring of MPEG 4-Nitrophenyl Carbonate is 
converted into secondary NH. The proton 
magnetic resonance spectra of MPEG-
PAMAM dendrimers and their 
corresponding derivatives have been 
recorded in CDCl3. In this NH signal of 
MPEG-PAMAM dendrimers appear at 7.27-
7.92 (s) ppm respectively. The position and 
presence of NH signal in the 1H-NMR 
spectra of final compounds conforms the 
secondary NH proton in MPEG-PAMAM 
dendrimers. All these observed facts clearly 
demonstrate that the MPEG 4-Nitrophenyl 
Carbonate is converted into secondary 
amino group as indicated and conforms the 
proposed structure of MPEG-PAMAM 
dendrimers. 
 
Drug Loading and entrapment efficiency  
The entrapment efficacy percentage of STV 
in PEGylated PAMAM dendrimer was 
increased when compared with PAMAM 
dendrimers (Table 1). Since noncovalent 
interactions with STV and PEGylated 
PAMAM dendrimer, such as hydrophobic 
interaction and hydrogen bonding were 
responsible for binding of drug molecules 
in interior cavities of dendrimer.  Moreover 
significant increase in entrapment of STV in 
PEGylated PAMAM dendrimers with 
respect to that of PAMAM dendrimers 
might due to more interaction of drug and 
mpeg at peripheral portion of dendrimers. 
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Table 1. Drug Entrapment and Hemolytic Studies 
 
Formulation % Drug entrapped % Hemolytic studies 
EDA-PAMAM dendrimer G4 27.32±0.45 15.97±1.17 
EDA-PAMAM dendrimer G5 41.67±1.29 23.51±1.35 
PEG-PAMAM dendrimer G4 51.87±1.56 1.37±0.82 
PEG-PAMAM dendrimer G5 69.94±0.97 1.54±0.75 
 
 
Fig. 1. Synthesis of MPEG attached PAMAM dendrimers 
 
 
                                                            
2a        2b 
 
Fig. 2a. Tem image of STV loaded G4 PEG PAMAM dendrimer, 2b. Tem image of STV 
loaded G5 PEG PAMAM dendrimer 
 
Surface Morphology  
The surface morphology of drug 
loaded PEGylated PAMAM dendrimers 
were confirmed by TEM micrographs (Fig. 
2a and 2b). Micrographs showed that more 
or less spherical shape dendrimers were 
formed by agglomeration. 
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Hemolytic Toxicity 
The result of haemolytic toxicity 
studies of non PEGylated amine terminated 
PAMAM dendrimers showed 15-25% 
toxicity whereas in PEGylated PAMAM 
dendrimers haemolysis (toxicity) of RBCs 
were reduced to 2% are present Table 1. 
The surface modification of PAMAM 
dendrimers by PEGylation reduces the 
haemolysis of RBCs and toxicity nature. 
Reduction of toxicity nature in PEGylated 
PAMAM dendrimers was due to inhibition 
interaction occurs between RBCs and 
quaterny ammonium ion.  
 
Stability 
Three months storage of STV loaded 
PEGylated PAMAM dendrimers at 40±20C 
showed no change in appearance and 
redispersing ability. Moreover there was no 
significant difference in potency and 
cumulative % drug release (Table 2 and Fig 
5). 
 
 
 
Fig 5. Drug release studies after storage of three months 
 
Table 2. Stability studies of Drug loaded PEG-PAMAM dendrimers 
 
Formulation Appearance % Drug release 
PEG-PAMAM dendrimer G4 Pale yellow color 50.77±1.56 
PEG-PAMAM dendrimer G5 Pale yellow color 68.85±1.75 
 
CONCLUSION 
In conclusion we designed PAMAM having 
PEG grafts as a novel drug carrier.  In every 
chain of the PAMAM dendrimers, PEG was 
combined to nullify the toxicity and make 
them compatible carrier. In the 
encapsulation of anti-HIV drug stavudine 
in the PEGylated PAMAM dendrimers 
showed increase amount when compared 
with non-PEGylated PAMAM dendrimers. 
In vitro drug release studied showed that 
PEGylated PAMAM dendrimers had 
controlled and extend drug release. 
Moreover hemolytic studies proved that 
PEGylated PAMAM dendrimers had less 
toxicity compared with nonPEGylated 
PAMAM dendrimers. Based on above 
studies we are able to suggest that 
PEGylated PAMAM dendrimers was one of 
ideal candidate for anti HIV drug therapy. 
But further extensive in vivo and kinetics 
studies required stapling them as novel 
candidate for drug delivery system.  
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